[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

111.P1.37 Hemoglobinopathies, excluding Thalassemia Poster II

Oral and Poster Abstracts
Poster Session
Sunday, December 6, 2009: 6:00 PM-8:00 PM
Hall E (Ernest N. Morial Convention Center)
A Genome-Wide Association Study of the Alloimmunization Responder Phenotype in Sickle Cell Disease

Daniel A Dworkis, BS1*, Nadia Timofeev, MS2*, Jacqueline N. Milton, BS2*, Stephen W Hartley2*, Mayetri Gupta, PhD2*, Paola Sebastiani, PhD2*, Clinton T. Baldwin, PhD3*, Efthymia Melista, BS3*, Jason Parente, BS3*, Karen Quillen, MD4 and Martin H Steinberg, MD5

1Boston University School of Medicine, Boston, MA
2Biostatistics, Boston University School of Public Health, Boston, MA
3Center for Human Genetics, Boston, MA
4Boston Medical Center, Boston, MA
5Department of Medicine/Division of Hematology and Oncology, Boston University School of Medicine, Boston, MA

Active Von Willebrand Factor (VWF) in Plasma of Sickle Cell Patients Is An Indicator of Disease Severity

Junmei Chen, PhD1, William Hobbs, MD, PhD2, Jennie Le1*, Peter J Lenting, PhD3*, Philip G De Groot, PhD4* and Jose A. Lopez, MD5

1Research, Puget Sound Blood Ctr., Seattle, WA
2Hematology, University of Washington, Seattle, WA
3Department of Clinical Chemistry and Hematology, University of Utrecht, The Netherlands, Utrecht, Netherlands
4Laboratory of Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht, Netherlands
5Puget Sound Blood Center, Seattle, WA

Adhesion Molecules Interaction with Markers of Lipid Metabolism, Hemolysis, Endothelial Dysfunction and  Medical Histories Among Steady-State Sickle Cell Anemia Patients

Bruno Antônio Veloso Cerqueira Sr.1*, Wendell Vilas Boas Sr.2*, Jorge Clarêncio Sr.2*, Daniela Andrade Jr.2*, Angela MD Zanette, MD3*, Mitermayer Galvão Reis2*, Jose Moura Neto Sr.2*, Rodrigo Silva Cesar Sr.2* and Marilda Souza Goncalves, Dr4*

1Universidade de Santa Cruz, Ilhéus, Brazil
2Centro de Pesquisas Gonçalo Moniz - FIOCRUZ, Salvador, Brazil
3Outpatient Unit, Fundacao Hemoba, Salvador, Brazil
4Molecular Biology, Centro de Pesquisa Gonçalo Muniz-Fiocruz, Salvador, Brazil

Assessment of Genotoxicity Associated with Hydroxyurea Therapy in Children with Sickle Cell Anemia

Jonathan M Flanagan, PhD1, Thad A. Howard, MS1*, Nicole Mortier, MHS, PA-C1*, Svetlana Avlasevich, B.S.2*, Matthew Smeltzer, MS3*, Song Wu, PhD3*, Stephen D. Dertinger, PhD2* and Russell E. Ware, MD, PhD1

1Hematology, St. Jude Children's Research Hospital, Memphis, TN
2Litron Laboratories, Rochester, NY
3Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN

Brain Imaginig in SCD Adults Patients: Correlation to TCD Image and Atoxic Contrast ( Microbubbles)

Paulo Bahia1*, Ana Leite2*, Orlando Veloso3*, Clarisse LOPES Lobo, ASH, MEMBER4 and Jorge Marcondes1*

1UFRJ, Rio de Janeiro, Brazil
2HEMORIO, Rio de Janeiro
3Ecodoppler SA, Rio de Janeiro, Brazil
4Hematology, HEMORIO, Rio De Janeiro, Brazil

Combining Fetal Hemoglobin and Reticulocytosis to Index Clinical Severity of Sickle Cell Disease in Children

Emily Riehm Meier, MD1, Colleen Byrnes, MS2*, Maxine Weissman, MT, ASCP3*, Pierre Noel, MD3*, Naomi L.C. Luban, MD4 and Jeffery L. Miller, MD2

1Hematology Division, Children's National Medical Center and Molecular Medicine Branch, NIDDK, NIH, Washington, DC
2Molecular Medicine Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
3Hematology Service, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD
4Hematology Division, Children's National Medical Center and Department of Pediatrics, The George Washington University Medical Center, Washington, DC

Comparison of Thrombin Generation of Sickle Cell Patients in Microparticle Rich and Microparticle Poor Plasma Using Thrombin Generation Assay (TGA)

Nirmish Shah, MD1, Marilyn J. Telen, MD2 and Thomas L. Ortel, MD, PhD3

1Pediatric Hem./Onc., Duke University Hospital, Durham, NC
2Medicine, Duke University Medical Center, Durham, NC
3Duke University Medical Center, Durham, NC

Diagnostic Complications of Thalassemic Hb Showa-Yakushiji (β110[G12] Leu→Pro),Observed in An African American Child with Co-Inherited Hb B2 (δ16[A13]Gly→Arg) and α-Thal-2  (-α3.7 deletion): Effects of Triple Globin Gene Abnormality On  Phenotype

Chinwe Obiaga, Medical, student1*, Niren Patel, MD1*, Hernan Sabio, MD2, Natalia Dixon, MD2, Steffen E. Meiler, MD3, Lina Zhuang, MD1*, Abdullah Kutlar, MD1 and Ferdane Kutlar, MD1

1Medicine, Medical College of Georgia, Augusta, GA
2Pediatrics, Wake Forest University, Winston Salem, NC
3Anesthesiology & Periop. Med., Medical College of Georgia, Augusta, GA

Effectiveness of Imatinib Therapy for a Patient with Sickle Cell Anemia and Chronic Myelocytic Leukemia

Julia L. Close, MD* and Richard Lottenberg, MD

Department of Medicine, Division of Hematology/Oncology, University of Florida, Gainesville, FL

Extracranial Internal Carotid Arterial Disease in Children with Sickle Cell Disease

David C Rees1*, Colin R Deane2*, Jack L Bartram1*, David Goss2*, Austin G Kulasekararaj3*, Keith Pohl4*, Sue Height1* and Swee Lay Thein3

1Department of Paediatric Haematology, King's College Hospital, London, United Kingdom
2Vascular Laboratory, King's College Hospital, London, United Kingdom
3Department of Haematology, King's College Hospital, London, United Kingdom
4Paediatric Neurology, King's College Hospital, London, United Kingdom

Functional Assessment for Children Hospitalized for Sickle Cell Pain: A New Paradigm

William T. Zempsky, MD1*, John M. Corsi, MBA2*, Kristin A. Loiselle, BS3*, Nathan Hagstrom, MD1, Tonya M. Palermo, PhD4* and James F. Casella, MD5

1Connecticut Children's Medical Center / University of Connecticut School of Medicine, Hartford, CT
2Connecticut Childrens Medical Center, Hartford, CT
3Connecticut Children's Medical Center, Hartford, CT
4Oregon Health & Sciences University, Portland, OR
5Pediatrics, Johns Hopkins Univ. School of Med., Baltimore, MD

Genetic Polymorphisms in NEDD4L Are Associated with Pulmonary Hypertension of Sickle Cell Anemia

Elizabeth S Klings, MD1, Daniel A Dworkis, BS2*, Amanda Sedgewick, MS3*, Stephen W Hartley3*, Ashley-Koch Allison, PhD4*, Marilyn J. Telen, MD5, Gregory J. Kato, MD6, Mark Gladwin, MD7, Paola Sebastiani, PhD3*, Clinton T. Baldwin, PhD8* and Martin H Steinberg, MD9

1The Pulmonary Center, R-304, Boston University Sch. of Med., Boston, MA
2Center for Human Genetics, Boston University School of Medicine, Boston, MA
3Biostatistics, Boston University School of Public Health, Boston, MA
4Department of Medicine, Duke University, Durham
5Medicine, Duke University Medical Center, Durham, NC
6Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
7Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
8Center for Human Genetics, Boston, MA
9Department of Medicine/Division of Hematology and Oncology, Boston University School of Medicine, Boston, MA

Genome-Wide Association for Silent Cerebral Infarction (SCI) in Sickle Cell Disease: The Silent Infarct Transfusion Trial (SIT) Cohort

Pallav Bhatnagar, PhD1*, Emily Barron Casella2*, Dan E Arking, PhD1* and James F. Casella, MD2

1McKusick-Nathans Institute of Genetic Medicine, School of Medicine, The Johns Hopkins University, Baltimore, MD
2Department of Pediatrics, Division of Pediatric Hematology, The Johns Hopkins University School of Medicine, Baltimore, MD

Hemoglobin E (β26Glu→Lys) Exhibits Altered Nitrite Reactivity

Camille J. Roche, Ph.D.1*, Tatiana C. Balazs2*, Qiuying Chen, Ph.D.2*, Juan C. Moreira1*, Joel M. Friedman, Ph.D.1* and Rhoda Elison Hirsch, Ph.D.3

1Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, NY
2Medicine, Albert Einstein College of Medicine, Bronx, NY
3Medicine and Anatomy & Structural Biology, Albert Einstein College of Medicine, Bronx, NY

Hydroxyurea Therapy Is Associated with Decreased Platelet Aggregation Responses and Activation in Sickle Cell Disease

Renata Proença-Ferreira, M.Sc.*, Tania F.G.S. Machado*, Fabiola Traina, M.D., Ph.D.*, Sara T.O. Saad, M.D., Ph.D., Fernando Ferreira Costa, Ph.D., M.D. and Nicola Conran, Ph.D.

Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil

Imbalance in Arachidonic Acid to Docosahexaenoic Acid Ratios in the Sickle Red Cell Is Associated with Inflammation

Yamaja Setty, PhD1, Suhita Gayen-Betal, PhD1*, Suba Krishnan, MD1*, Maureen Meier, RN2*, Michele Cahill3* and Marie J. Stuart, MD1*

1Pediatrics, Thomas Jefferson University, Philadelphia, PA
2Drexel University College of Medicine, Marian Anderson Comprehensive Sickle Cell Center, Nelson 2130, Philadelphia, PA
3Hematology, St Christopher's Hospital for children, Philadelphia, PA

Impact of Hydroxyurea On Peri-Operative Management and Outcomes in Children with Sickle Cell Anemia

Masanori Hayashi, MD1*, Agustin Calatroni, MS2*, Brittany Herzberg1* and Courtney Thornburg, MD, MS1

1Pediatrics, Duke University Medical Center, Durham, NC
2Rho, Inc., Chapel Hill, NC

LBH589 (panobinostat): A Potential Novel Anti-Switching Therapy

Abdullah Kutlar, MD1, Niren Patel, MBBS2*, Celalettin Ustun, MD1, Kavita Natarajan, MBBS1, Anand Jillella, MD1, Betsy Clair2*, Ferdane Kutlar2*, Rosemary Chandler, BSN, RN, OCN3*, Steffen E. Meiler, MD4 and Kapil N. Bhalla, MD5

1Medical College of Georgia, Augusta, GA
2Sickle Cell Center, Medical College of Georgia, Augusta, GA
3Medical College of GA, Augusta, GA
4Anesthesiology & Periop. Med., Medical College of Georgia, Augusta, GA
5Medical College of Georgia Cancer Center, Augusta, GA

Liver Hypoxia and Tissue Injury Are Specific to Sickle Cell Mice in An Experimental Model of Sickle Cell Vaso-Occlusion

Lewis L. Hsu, MD, PhD1*, Audrey C Noguchi2*, Constance Noguchi, PhD3*, Katherine C Wood, Ph.D.4*, James G Taylor VI, MD5*, Gregory J. Kato, MD6, Mark Gladwin, MD7 and Bhalchandra Diwan, PhD8*

1Hematology, Children's National Medical Center, Washington, DC
2Vascular Medicine Branch, NHLBI, Bethesda, MD
3Molecular Medicine Branch, NIDDK, NIH, Bethesda, MD
4Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD
5Pulmonary and Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD
6Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
7Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
8Basic Science Program, SAIC-Frederick, NCI at Frederick, Frederick, MD

Low Ascorbate Levels in Transfused Patients Are Associated with Correlates of Vascular Damage in Sickle Cell Disease

Susan Claster, MD1, Susan Carson2*, Thomas C Hofstra, MD3*, Thomas Coates1 and John C Wood4*

1Children's Hospital Los Angeles, Los Angeles, CA
2Children's Center for Cancer & Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA
3Hematology/oncology, Childrens Hospital Los Angeles, Los Angeles, CA
4Children's Hospital of Los Angeles, Los Angeles, CA

Lower Ferritin Concentrations Are Associated with Decreased Hemolysis in Sickle Cell Disease Children without Iron Overload

Oswaldo L Castro, MD1, Mehdi Nouraie, M.D., Ph.D.1*, Lori Luchtman-Jones, MD2, Xiaomei Niu, M.D.1*, Caterina Minniti, M.D.3*, Andrew D. Campbell, MD4, Sohail R Rana, MD5*, Gregory J. Kato, MD6, Mark Gladwin, MD7 and Victor R. Gordeuk, MD1

1Center for Sickle cell Disease, Howard University, Washington, DC
2Children's National Medical Center, Washington, DC
3Vascular Medicine Branch, NHLBI, Bethesda, MD
4Pediatric Hematology/Oncology, Univ. of Michigan Med. Ctr., Ann Arbor, MI
5Department of Pediatric and Child Health, Howard University Hospital, Washington, DC
6Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
7Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

Measurement of Urine Pyridinoline and Deoxypyridinoline as Markers of Increased Bone Degradation in Sickle Cell Disease

Erfan Nur, MD1*, Willem Mairuhu2*, Dees P. Brandjes, MD, PhD3*, Ton van Zanten2*, Bart J. Biemond, MD, PhD4 and Hans-Martin Otten, MD, PhD5*

1Internal Medicine, Slotervaart Hospital, Amsterdam, Netherlands
2Department of Clinical Biochemistry, Slotervaart Hospital, Amsterdam, Netherlands
3Department of Internal Medicine, Slotervaart hospital, Amsterdam, Netherlands
4Academic Medical Center, Amsterdam, Netherlands
5Department of Internal Medicine, Slotervaart Hospital, Amsterdam, Netherlands

Modulation of Hemodynamics and Adhesion of Sickle Red Blood Cells On Endothelial Cells Treated with Hydroxycarbamide

Emmanuelle Verger1*, Sandrine Laurance1*, Arlette Bruel2*, Damien Schoëvaërt2*, Marie-Helene Odievre3*, Odile Feneteau4*, Claudine Lapouméroulie1* and Jacques Elion1*

1INSERM UMR763, Paris, France
2INSERM U553, Paris, France
3Hôpital Louis Mourier, Colombes, France
4Hôpital Robert Debré, Paris

Morphine Pharmacokinetics in Sickle Cell Disease: Implications for Pain Management

Deepika S. Darbari1*, Michael Neely, MD2*, John VandenAnker, MD3* and Sohail R Rana, MD4*

1Pediatric Hematology/Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
2Pediatric Infectious Disease and Lab of Applied Pharmacokinetics, University of Southern California, Los Angeles, CA
3Pediatrics and Clinical Pharmacology, Childrens National Medical Center, Washington, DC
4Department of Pediatric and Child Health, Howard University Hospital, Washington, DC

Movement of Hydroxyurea Across Cell Membranes Is Mediated by Specific Solute Carrier (SLC) Transporters

Aisha L. Walker, PhD1*, Ryan M Franke, PhD2*, Alex Sparreboom, PhD2* and Russell E. Ware, MD, PhD1

1Hematology, St. Jude Children's Research Hospital, Memphis, TN
2Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN

Neuropathic Vs. Nociceptive Pain in Adolescent Sickle Cell Disease (SCD) Evaluated by a Computer-Based Self-Assessment Pain Tool

Richard J. Labotka, MD1, Robert E. Molokie, MD2*, A. Kyle Mack, MD3, Alexis A Thompson, MD, MPH4, Young Ok Kim, PhD5* and Diana J Wilkie, PhD6*

1Pediatric Hematology and Oncology, University of Illinois at Chicago, Chicago, IL
2Hematology - Sickle Cell Department, University of Illinois, Chicago, IL
3Children's Memorial Hospital, Chicago, IL
4Hematology, Oncology & Stem Cell Transplant, Children's Memorial Hospital, Chicago, IL
5Behavioral Health Science, University of Illinois at Chicago, Chicago, IL
6College of Nursing, University of Illinois at Chicago, Chicago, IL

Patterns of Analgesic Utilization in the Multicenter Study of Hydroxyurea (MSH)

Samir K. Ballas, MD1, William F. McCarthy, Ph., D.2*, Robert I Bauseman, PhD3*, Oswaldo L Castro, MD4, Paul S. Swerdlow, MD5, Wally Smith6*, Myron A Waclawiw, PhD7* and Bruce A Barton, PhD8*

1Medicine, Jefferson Medical College, Philadelphia, PA
2Statistics, Maryland Medical Research Institute, Baltimore, MD
3Statistics, Maryland Medical Research Institute, Baltimore
4Center for Sickle cell Disease, Howard University, Washington, DC
5Barbara Ann Karmanos Cancer Inst., Wayne State University, Detroit, MI
6Virginia Commonwealth University, Richmond, VA
7Biostatistics Research, NIH, Bethesda
8Statistics, Maryland Medical Research Institute, Baltomore

Plasma Protein Oxidation and Triglyceride Levels in Sickle Cell Anemia

Yesim Oztas, MD1*, Selma Unal, MD2* and Nuriman Ozgunes, PhD1*

1Biochemistry, Hacettepe Medical School, Ankara, Turkey
2Pediatric Hematology, Mersin Medical School, Mersin, Turkey

Proteomic-Based Approach for Biomarker Discovery to Predict Silent Cerebral Infarct in Patients with Sickle Cell Disease

Lisa M. Williams, MD1, Zongming Fu, PhD1*, Pratima Dulloor2*, William J Savage, MD1, Emily Barron-Casella, PhD1*, John J. Strouse, MD, PhD1, Michael R. DeBaun, MD, MPH3, Jennifer Van Eyk, PhD4*, Allen Everett, MD2* and James F. Casella, MD1

1Division of Pediatric Hematology, Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD
2Pediatric Cardiology, Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD
3Biostatistics and Neurology, Pediatrics, Washington University, Saint Louis, MO
4Division of Cardiology, Internal Medicine and the Bayview Proteomics Center, The Johns Hopkins University School of Medicine, Baltimore, MD

Reduction of Urinary Bladder Activity in Transgenic Sickle Cell Disease Mice

Mário Angelo Claudino, B.Sc., Ph.D1*, Carla Fernanda Franco-Penteado, B.Sc., M.Sc., Ph.D2*, Marcus A.F. Corat, B.Sc., M.Sc., Ph.D3*, Ana Paula Gimenes, B.Sc3*, Kleber Yotsumoto Fertrin, MD2*, Luiz Augusto C Passos, B.Sc., M.Sc., Ph.D3*, Edson Antunes, B.Sc., M.Sc., Ph.D1* and Fernando Ferreira Costa, Ph.D., M.D.2

1Department of Pharmacology, University of Campinas - UNICAMP, Campinas, Brazil
2Hematology and Hemotherapy Center, University of Campinas - UNICAMP, Campinas, Brazil
3Multidisciplinary Center for the Investigation of Biological Science in Laboratory Animals, University of Campinas - UNICAMP, Campinas, Brazil

Reliability of Tricuspid Regurgitant Jet Velocity Measurements in Children and Young Adults with Sickle Cell Disease

Robert I. Liem, MD1, Stephanie A. Pelligra, BS1*, Amy D. Shah, MD2*, Richard J. Labotka, MD3, Luciana T. Young, MD2* and Alexis A. Thompson, MD, MPH1

1Hematology, Oncology & Stem Cell Transplant, Children's Memorial Hospital, Chicago, IL
2Cardiology, Children's Memorial Hospital, Chicago, IL
3Pediatric Hematology and Oncology, University of Illinois at Chicago, Chicago, IL

Sickle Cell Genetic Markers: Geographic Distribution and Relation to Pain Outcomes in Multicenter Study of Hydroxyurea in Sickle Cell Anemia

Samir K. Ballas, MD1, William F. McCarthy, Ph., D.2*, Robert L Bauserman, PhD2*, Oswaldo L Castro, MD3, Myron A Waclawiw, PhD4* and Bruce A Barton, PhD5*

1Medicine, Jefferson Medical College, Philadelphia, PA
2Statistics, Maryland Medical Research Institute, Baltimore, MD
3Center for Sickle cell Disease, Howard University, Washington, DC
4Biostatistics Research, NIH, Bethesda
5Statistics, Maryland Medical Research Institute, Baltomore

Sickle Cell Leg Ulcers Are Associated with Hyperuricemia, Hemolysis, Pulmonary Hypertension and Death

Caterina P. Minniti, MD1, Mariana Hildesheim2*, Vandana Sachdev, MD3*, Darlene Allen2*, Oswaldo Castro, MD4*, James G Taylor VI, MD5* and Gregory J. Kato, MD6

1Pulmonary and Vascular Medicine, National Institutes of Health, Chevy Chase, MD
2Pulmonary and Vascular Medicine Branch, NHLBI, National Institutes of Health, Bethesda, MD
3Translational Medicine Branch, National Institutes of Health, Bethesda, MD
4Center for Sickle Cell Disease, Howard University, Washington, DC
5Pulmonary and Vascular Medicine Branch, NIH/NHLBI, Bethesda, MD
6Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

The Complex Relationship Between Sickle Cell Disease and Depression

Soheir S. Adam, M.D.1, Charlene Flahiff, M.S.2*, Mary R Abrams, MPH2*, Marilyn J. Telen, MD2 and Laura M. De Castro, MD2

1Medicine/ Hematology, UNC, Chapel Hill, NC
2Medicine, Comprehensive Sickle Cell Center, Duke University, Durham, NC

The HDAC Inhibitors Trichostatin A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA) Exhibit Multiple Modalities of Benefit for the Vascular Pathology of Sickle Disease

Robert P Hebbel, MD1, Gregory M. Vercellotti, MD2, Betty Pace, MD3, Anna Solovey, M.D.1*, Rahn Kollander1*, Chine Abanonu1*, Julia Nguyen, BS4*, Julie V. Vineyard, BS4*, John D Belcher, Ph.D.5*, Fuad Abdulla1*, Shade Osifuye1*, John W. Eaton, PhD6, Robert Kelm, MD7* and Arne Slungaard, MD8

1Hematology/Oncology/Transplantation Division, Dept. of Medicine, University of Minnesota, Minneapolis, MN
2Medical School, University of Minnesota, Minneapolis, MN
3Univ. of Texas at Dallas, Richardson, TX
4Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
5University of Minnesota
6University of Louisville, James Graham Brown Cancer Ctr., Louisville, KY
7Biochemistry, University of Vermont, Burlington, VT
8University of Minnesota, Minneapolis, MN

Thrombin Generation in Sickle Cell Disease: Insights From Computerized Automated Thrombography

Suhita Gayen Betal1*, Gregory J Kato2, Marlene Peters Lawrence2*, Catherine Seamon3*, Yamaja Setty, PhD1, Marie J. Stuart, MD1* and Suba Krishnan, MD1*

1Pediatrics, Thomas Jefferson University, Philadelphia, PA
2Vascular Medicine Branch, NHLBI, Bethesda, MD
3NHLBI, Bethesda

Type I Methemoglobinemia Caused by the Cytochrome b5 Reductase 806C>T Mutation Is Present in the Indigenous Evenk People of Yakutia

Tatyana Burtseva1*, Tatiana Ammosova, PhD2*, Josef T. Prchal, MD3, Vyacheslav Chasnyk, MD4*, Sergei Nekhai, PhD2* and Victor R. Gordeuk, MD2

1The Yakut Research Center of Siberian Department of Russian Academy of Medicine, Yakutsk, Russia
2Howard University, Washington, DC
3University of Utah, Salt Lake City, UT
4St.Petersburg Pediatric Academy, St.Petersburg, Russia

White Matter Integrity and Core Cognitive Function in Children Diagnosed with Sickle Cell Disease

Nadia Scantlebury1*, Donald Mabbott2*, Garland Jones1*, Laura Janzen1* and Isaac Odame2

1The Hospital for Sick Children, Toronto, ON, Canada
2University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada

*signifies non-member of ASH